Scientific Sessions

Presidential Collage 3

Scientific Sessions: A meeting of health and hope

On the cusp of its 100th year, the American Heart Association’s CEO reiterates the association's vision during the Presidential Session.

cover of the on-site meeting guide

#AHA23 On-Site Meeting Guide

On-Site Meeting Guide

Maxresdefault 65561fbdb9acc

Watch: Scientific Sessions 2023 Day 2 | Sunday, Nov. 12

Aha23 Syny Base 1

Scientific Sessions 2024

Panel of speakers

Getting to the Heart of Stroke™

Hqdefault 6554fd1be4044

Watch: Scientific Sessions 2023 | Day 1, Saturday, Nov. 11

AHAtv provides full coverage of Day 1's exciting sessions and events.

Audience shot

Late-breaking science| Achieving equity in prevention

Health care worker-led trial improves hypertension control, automated pharmacy referral for statin prescribing, SBP levels improving CVD outcomes and reducing hypertension in low-income population.

audience shot

Novel mechanisms for lipid-lowering therapy

Editing the PCSK9 gene, first-in-human trial of lepodisiran, new PCSK9 antibody and statins performance in people with HIV highlight four trials.

LBS 08 panelists

Late-breaking science: AI at the bedside

AI-powered stethoscope, speech analysis for HF, interpreting ECGs with AI and prognostic tool for predicting MACE.

Lbs05 Panel Web

Shocking decisions in AFib care

Trials’ results highlight the risks and benefits of oral anticoagulation, the superiority of dual direct cardioversion in patients with obesity and the potential for a novel factor XI inhibitor to reduce bleeding in patients with high risk of stroke.

Lbs04 Panel2 Web

Drugs, diet and delivery can optimize hypertension outcomes

Findings evaluate dietary sodium reduction, postpartum blood pressure, an investigational RNA interference therapeutic agent and BP control and dementia risk.

Jane E. Freedman, MD, Ann Marie Schmidt, MD, M. Benjamin Shoemaker, MD, MSCI, J. Kevin Donahue, MD

Established lecture to present new research developments

Atrial fibrillation experts examine critical needs and potential therapeutic possibilities for the prevalent condition

Randi Foraker, PhD, MA, FAHA, FAMIA, Jessica L. Mega, MD, MPH

Artificial intelligence shows promise and pitfalls

AI can be a benefit in cardiovascular care, but a responsible approach is needed

Clyde W. Yancy, MD, MSc, MACC, FAHA, and Reinier Boon, PhD

Age: Is it a number, or a biology?

Champions of cardiovascular health and investigators in the aging domain unite to address age-old questions and present innovative insights

Tweets by AHAScience

Joseph C. Wu, MD, PhD, FAHA

Teamwork matters

audience shot

Heart failure late-breaking science

Valentin Fuster, MD, PhD, José María Castellano, MD, PhD, Daniel José Piñeiro, MD, and Clara Chow, MBBS, PhD.

Changing the course of medicine

Opening Session Collage

Your backstage pass to Scientific Sessions 2023

A. Michael Lincoff, MD

Weight-loss drug reduced secondary CV risk in people with overweight or obesity without diabetes

From left: Christopher Rajkumar, MD, MRC, Jeffrey L. Carson, MD, MACP; Stefan James, MD.

Trials’ results suggest new approaches to reducing CVD risk and symptoms

David Morrow, MD, MPH, FAHA, and Susanna Price, MD, PhD

A comprehensive view of cardiogenic shock

Chiadi Ndumele, MD, PhD, MHS, FAHA; Janani Rangaswami, MD, FACP, FCRS, FAHA, and Sheryl L. Chow, PharmD, FCCP, FAHA, FHFSA

Metabolic risk factors can complicate kidney, cardiovascular health

Nobel Laureate Aha

Q&A With Nobel Laureate Edvard Moser, PhD

Marta Sitges, MD, and Patrick T. O’Gara, MD

Looking to TAVI’s future

Rakesh Gopinathannair, MD, MA, FAHA

Sudden impact

image of stars

American Heart Association selects six Distinguished Scientists for 2023